Zhejiang Hisun Pharma will invest $6 million in Photolitec LLC, a brand new cancer startup located in Buffalo, NY. Hisun committed to sending Photolitec $2 million immediately and $1 million each year for the next four years, plus milestones. The deal gives Hisun right of first refusal for compounds being developed in conjunction with Photolitec’s Photodynamic Therapy for oncology. More details....

Stock Symbol: (SHA: 600267)     Share this with colleagues: